Alex Biese

The FDA has granted fast track designation to HLD-0915 for metastatic castration-resistant prostate cancer.

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

Among patients with advanced gastrointestinal stromal tumors, Gleevec and Mektovi was associated with benefits in progression and survival.

Long-term follow-up data from the phase 3 MANIFEST 2 clinical trial have been revealed.

Among patients with chronic lymphocytic leukemia, immunoglobulin replacement therapy is not associated with a reduced risk of serious infections.

The FDA approved Hernexeos for adults with unresectable or metastatic non-squamous non-small cell lung cancer.

Epkinly with Rituxan and Revlimid, compared to Rituxan and Revlimid alone, reduced risk of progression or death by 79%.

An artificial intelligence-based image analysis model has more accurately predicted cancer biomarkers and outcomes compared with conventional methods.

The U.S. FDA granted accelerated approval to Modeyso for patients with diffuse midline glioma with an H3 K27M mutation with progressive disease.

The FDA approved an investigational new drug application for ABT-301, clearing the way for a new clinical trial in metastatic colorectal cancer to begin.

CURE spoke with experts about radical cystectomy, or surgical removal of the bladder, for patients with bladder cancer.

CURE spoke with a thoracic surgeon about the impact of minimally invasive surgery for patients.

How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.

CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine for patients with advanced kidney cancer.

Antihistamines may be associated with survival improvement in patients with metastatic urothelial carcinoma receiving Tecentriq.

CURE spoke with experts about what life is like for patients in the survivorship care period.

Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer.

Dr. Brian Czerniecki, of Moffitt Cancer Center, led a CURE Educated Patient® Updates in Metastatic Breast Cancer event, and provided subsequent updates.

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.

The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma.

Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

In patients with advanced squamous non–small cell lung cancer, ivonescimab plus chemo was associated with progression-free survival results.

The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

In some patients with advanced triple-negative breast cancer, Trodelvy plus Keytruda was associated with an improvement in disease progression.

Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis, according to the ROMEI clinical trial.

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were treated in the advanced setting.

Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks.

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, replacing single-agent treatments.

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.